Publications by authors named "D Guber"
Article Synopsis
- Oligoclonal bands (OCBs) found in cerebrospinal fluid (CSF) are important for diagnosing multiple sclerosis (MS) and may also play a role in autoimmune encephalitis (AIE) with NMDA receptor antibodies.
- The study analyzed 21 patients divided into two groups: those with only AIE antibodies and those who also tested positive for OCBs, focusing on cognitive impairments and associated diagnostic tests.
- Results showed that patients with both OCBs and NMDA antibodies had higher CSF cell counts and more severe language and attention deficits, highlighting OCBs as potential markers for disease severity in AIE.
Background: The central vein sign (CVS) has been proposed as a novel MRI biomarker to improve diagnosis of pediatric-onset MS (POMS). However, the role of CVS in POMS progression has yet to be discovered.
Objectives: To investigate the appearance of CVS and its correlation with POMS disease progression.
Background: As immunity against SARS-COV-2 wanes following first and second doses of vaccination, a third dose is administered in several countries around the world. Similarly to the first doses, risks related to vaccination and humoral immune response in patients with multiple sclerosis (MS) need to be assessed.
Objective: Characterize safety and humoral immune response following the third dose of COVID-19 vaccination in a large cohort of MS patients.
Meninges, or the membranous coverings of the brain and spinal cord, play host to dozens of morbid pathologies. In this study we provide a method to isolate the leptomeningeal cell layer, identify leptomeninges in histologic slides, and maintain leptomeningeal fibroblasts in in vitro culture. Using an array of transcriptomic, histological, and cytometric analyses, we identified ICAM1 and SLC38A2 as two novel markers of leptomeningeal cells in vivo and in vitro.
View Article and Find Full Text PDFAppropriate immune response following COVID-19 vaccination is important in the context of disease-modifying treatments (DMTs). In a prospective cross-sectional study, we determined SARS-COV-2 IgG response up to 6 months following PfizerBNT162b2 vaccination in 414 multiple sclerosis (MS) patients and 89 healthy subjects. Protective response was demonstrated in untreated MS patients (N = 76, 100%), treated with Cladribine (N = 48, 100%), Dimethyl fumarate (N = 35, 100%), Natalizumab (N = 32, 100%), and Teriflunomide (N = 39, 100%), similarly to healthy subjects (N = 89, 97.
View Article and Find Full Text PDF